MRNA Q4 & FY25 Outlook: 🔹 Q4 Results: • EPS: -2.91 (Missed Est. -2.68) • Revenue: 966M (Beat Est. 942.8M, -66% y/y) • COVID-19 Vaccine Rev: 923M (In Line) • Op. Loss: -1.25B (Est. -1.13B, vs. 6M profit y/y) • Cash & Equiv.: 1.93B (Est. 2.12B) 🔹 FY25 Guidance: • Revenue: 1.5B-2.5B (Est. 2.43B) • CapEx: ~400M (Est. 468.9M) • Cost Cuts: 1B by 2025-end • Cash & Inv. (Dec 31): 9.5B Q4 loss includes 200M in non-cash charges for manufacturing resizing.